Treatment of diabetes in long-term care facilities: A primary care approach

Clinical Diabetes

Volumn 26, Issue 4, 2008, Pages 152-156

  Johnson, Eric L ^a,b   Brosseau, James D ^a   Sobule, Matt ^b   Kolberg, Jon ^b  

^a ALTRU HEALTH SYSTEM   (United States)

^b UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; DETEMIR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV; EXENDIN 4; GLULISINE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; NATEGLINIDE; PERINDOPRIL; REPAGLINIDE; SIMVASTATIN; SITAGLIPTIN; SULFONYLUREA; UNCLASSIFIED DRUG;

AGING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; EPIDEMIC; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; LIFE EXPECTANCY; LONG TERM CARE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NURSING HOME; PATIENT MONITORING; POLYPHARMACY; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; REVIEW; SIDE EFFECT;

EID: 54249137681     PISSN: 08918929     EISSN: None     Source Type: Journal    
DOI: 10.2337/diaclin.26.4.152     Document Type: Review

References (36)

1. International Diabetes Federation: IDF Atlas [article online]. Available from www.idf.org. Accessed April 2008
2. Omnicare, Inc.: Prevalence of diabetes in 500,000 nursing home residents in the United States (Proprietary data from Omnicare, Inc., 2004, cited in Zarowitz BJ, Tangalos EG, Hollenack K, O'Shea T: Application of evidence-based principles of care in older persons: Issue 3: management of diabetes mellitus. J Am Med Direct Assoc 7:234-240, 2006
3. Haines ST: The diabetes epidemic: can we stop the spread? Pharmacotherpy 23:1227-1231, 2003
4. Travis SS, Buchanan RJ, Wang S, Kim M: Analysis of nursing home residents on admission. J Am Med Direct Assoc 4:320-327, 2004
5. American Diabetes Association: Standards of medical care in diabetes [Position Statement]. Diabetes Care 28 (Suppl. 1):S4-S36, 2005
6. American Medical Directors Association: Managing Diabetes in the Long-Term Care Setting: Clinical Practice Guideline. Columbia, Md., American Medical Directors Association, 2002
7. U.K. Prospective Diabetes Study Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
8. American Diabetes Association: Standards of medical care in diabetes [Position Statement]. Diabetes Care 31 (Suppl. 1): S12-S54, 2008
9. Misbin RI: Evaluating the safety of diabetes drugs: perspective of a Food and Drug Administration insider. Diabetes Care 28:2573-2576, 2005
10. Mooradian AD: Drug therapy of non-insulin dependent diabetes mellitus in the elderly. Drugs 51:931-941, 1996
11. Gregorio F, Ambrosi F, Filipponi P, Manfrini S, Testa I: Is metformin safe enough for aging type 2 diabetic patients? Diabetes Metab 22:43-50, 1996
12. Jennings PE: Oral antihyperglycemics: considerations in older patients with non-insulin dependent diabetes mellitus. Drugs Aging 10:323-331, 1997
13. Chipkin SR: How to select and combine oral agents for patients with type 2 diabetes. Am J Med 118 (Suppl. 5A):4S-13S, 2005
14. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE: Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298:1180-1188, 2007
15. Nissen SE, Wolfski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457-2471, 2007
16. Fonseca VA, Kulkarni KD: Management of type 2 diabetes: oral agents, insulin, and injectables. J Am Dietetic Assoc 4 (Suppl. 1):S29-S33, 2008
17. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R: Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 27:256-263, 2004
18. American College of Physicians: ACP Diabetes Care Guide: A Team-Based Practice Manual and Self-Assessment Program. Philadelphia, Pa., American College of Physicians, 2007
19. Szoke E, Shrayyef MZ, Messing S, Woerle HJ, van Haeften TW, Meyer C, Mitrakou A, Pimenta W, Gerich JE: Effect of aging on glucose homeostasis: accelerated deterioration of beta-cell function in individuals with impaired glucose tolerance. Diabetes Care 31:539-543, 2008
20. DeFronzo R, Bonadonna R, Ferrannini E: Pathogenesis of NIDDM. In International Textbook of Diabetes Mellitus. 2nd ed. Alberti K, Zimmet P, DeFronzo R, Eds. New York, Wiley and Sons, 1997, p. 635-711
21. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC: Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102-110, 2003
22. Meneghini LF, Rosenberg KH, Koenen C, Merilainen MJ, Luddeke HJ: Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab 9:418-427, 2007
23. Haas LB: Optimizing insulin use in type 2 diabetes: role of basal and prandial insulin in long-term care facilities J Am Med Direct Assoc 8:502-510, 2007
24. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B: Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 29:1963-1972, 2006
25. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ: Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358:1887-1898, 2008
26. Dahlöf B, Lindholm LH, Hansson L, Scherstén B, Ekbom T, Wester PO: Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP Hypertension). Lancet 338:1281-1285, 1991
27. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289:2560-2572, 2003
28. National Cholesterol Education Program: Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001
29. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110:227-239, 2004
30. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM: Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495-1504, 2004
31. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291:1071-1080, 2004
32. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH; CARDS investigators: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364:685-696, 2004
33. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E: Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292:1307-1316, 2004
34. Aronow WS, Ahn C: Incidence of new coronary events and new atherothrombotic brain infarction in older persons with diabetes mellitus, prior myocardial infarction and serum low density lipoprotein cholesterol > 125 treated with statin. J Gerontol Series A Biol Sci Med Sci 57:M747-M750, 2002
35. Joseph J, Koka M, Aronow WS: Prevalence of a hemoglobin A1C less than 7.0%, of a blood pressure less than 130/80 mm Hg, and of a serum low-density lipoprotein cholesterol less than 100 mg/dL in older patients with diabetes mellitus in an academic nursing home. J Am Med Direct Assoc 9:51-54, 2008
36. Rivzi AA: Management of diabetes in older adults. Am J Med Sci 333:35-47, 2007